The bleeding time is used by many nephrologists to predict risk of hemorrha
ge before percutaneous kidney biopsy. Developed in 1910, the bleeding time
is a nonspecific test that may be prolonged in multiple disease stales. Whe
n accompanied by a platelet count, hematocrit, and a thorough investigation
of family or personal history of bleeding, the bleeding time is the best p
redictor of hemorrhagic risk in patients with kidney disease. Because there
is a small but significant risk of bleeding with percutaneous kidney biops
y, a prolonged bleeding time should be treated with 1-deamino-8-D-arginine
vasopressin, cryoprecipitate, estrogens, or dialysis as indicated before bi
opsy. Treating all patients with 1-deamino-8-D-arginine vasopressin without
checking bleeding times may be cost-ineffective when compared with treatin
g only those patients with prolonged bleeding times. Curr Opin Nephrol Hype
rtens 8:715-718. (C) 1999 Lippincott Williams & Wilkins.